0
     

Report Added
Report already added
Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 2, 11, 16, 1, 3, 105 and 18 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Traumatic Brain Injury - Overview
Traumatic Brain Injury - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Traumatic Brain Injury - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Traumatic Brain Injury - Companies Involved in Therapeutics Development
Traumatic Brain Injury - Drug Profiles
Traumatic Brain Injury - Dormant Projects
Traumatic Brain Injury - Discontinued Products
Traumatic Brain Injury - Product Development Milestones
Featured News & Press Releases
Feb 22, 2022: Alpha Cognition announces positive neuroprotection data from pre-clinical study of ALPHA-1062 for Traumatic Brain Injury
Feb 11, 2022: NFL legend Brett Favre and Odyssey Health, involved with human trials of first drug treatment for concussion
Feb 08, 2022: Vasopharm announces post hoc analyses of clinical trials in traumatic brain injury
Jan 18, 2022: Wesana Health announces positive findings from animal study on novel depression treatment protocol combining psilocybin and cannabidiol
Jan 11, 2022: Wesana Health granted US FDA Pre-IND meeting for SANA-013
Jan 10, 2022: Odyssey Group International receives donation to support a treatment for concussion and forms community partnership with the Erase PTSD Now Foundation
Dec 22, 2021: American CryoStem announces completion of patient recruitment for its Post-Concussion Syndrome (PCS) ATCELL(TM) phase I clinical trial
Dec 06, 2021: Alpha Cognition announce data from pre-clinical study of ALPHA-1062 for traumatic brain injury
Nov 18, 2021: Ventus Therapeutics to present data for novel brain-penetrant NLRP3 small molecule inhibitors for the treatment of inflammatory and neurological diseases
Nov 01, 2021: SanBio announces publication comparing outcome measures for persons with chronic traumatic brain injury in expert review of neurotherapeutics
Oct 25, 2021: NeuroTrauma Sciences supports University of Arizona College of Medicine - Phoenix Neurotrauma Research with challenge grant award
Oct 19, 2021: Odyssey Group International files patent on novel breath-propelled nasal delivery device
Oct 04, 2021: U.S. Senate Defense Bill includes NervGen supported language on promise of brain plasticity therapeutics for traumatic brain injury
Sep 22, 2021: Odyssey Group International begins enrolling subjects for phase 1 clinical trial to treat concussion
Sep 01, 2021: Odyssey Group International approved to start human trial to treat concussion
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Traumatic Brain Injury, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Companies, 2022 (Contd..3)
Number of Products under Development by Companies, 2022 (Contd..4)
Number of Products under Development by Companies, 2022 (Contd..5)
Number of Products under Development by Companies, 2022 (Contd..6)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Companies, 2022 (Contd..7)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Target, 2022 (Contd..2)
Number of Products by Stage and Target, 2022 (Contd..3)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Traumatic Brain Injury - Pipeline by Abliva AB, 2022
Traumatic Brain Injury - Pipeline by AegisCN LLC, 2022
Traumatic Brain Injury - Pipeline by AivoCode LLP, 2022
Traumatic Brain Injury - Pipeline by AlphaCognition Inc, 2022
Traumatic Brain Injury - Pipeline by ALSP Inc, 2022
Traumatic Brain Injury - Pipeline by AlzeCure Pharma AB, 2022
Traumatic Brain Injury - Pipeline by American CryoStem Corp, 2022
Traumatic Brain Injury - Pipeline by Amgen Inc, 2022
Traumatic Brain Injury - Pipeline by Anagin Inc, 2022
Traumatic Brain Injury - Pipeline by Angion Biomedica Corp, 2022
Traumatic Brain Injury - Pipeline by Anida Pharma Inc, 2022
Traumatic Brain Injury - Pipeline by Annovis Bio Inc, 2022
Traumatic Brain Injury - Pipeline by AntiRadical Therapeutics LLC, 2022
Traumatic Brain Injury - Pipeline by Aptinyx Inc, 2022
Traumatic Brain Injury - Pipeline by Astrocyte Pharmaceuticals Inc, 2022
Traumatic Brain Injury - Pipeline by Astrogen Ltd, 2022
Traumatic Brain Injury - Pipeline by Athersys Inc, 2022
Traumatic Brain Injury - Pipeline by Avanir Pharmaceuticals Inc, 2022
Traumatic Brain Injury - Pipeline by B Cell Solutions Inc, 2022
Traumatic Brain Injury - Pipeline by Bessor Pharma LLC, 2022
Traumatic Brain Injury - Pipeline by Beyond Barriers Therapeutics Inc, 2022
Traumatic Brain Injury - Pipeline by Biogen Inc, 2022
Traumatic Brain Injury - Pipeline by BioIncept LLC, 2022
Traumatic Brain Injury - Pipeline by Bioquark Inc, 2022
Traumatic Brain Injury - Pipeline by Biosplice Therapeutics Inc, 2022
Traumatic Brain Injury - Pipeline by Brain-Gen LLC, 2022
Traumatic Brain Injury - Pipeline by Braxia Scientific Corp, 2022
Traumatic Brain Injury - Pipeline by CalciMedica Inc, 2022
Traumatic Brain Injury - Pipeline by Calico Life Sciences LLC, 2022
Traumatic Brain Injury - Pipeline by CavoGene LifeSciences, 2022
Traumatic Brain Injury - Pipeline by CellCure, 2022
Traumatic Brain Injury - Pipeline by Cellvation Inc, 2022
Traumatic Brain Injury - Pipeline by CereSpir Inc, 2022
Traumatic Brain Injury - Pipeline by Chimerix Inc, 2022
Traumatic Brain Injury - Pipeline by Chrysalis BioTherapeutics Inc, 2022
Traumatic Brain Injury - Pipeline by Claritas Pharmaceuticals Inc, 2022
Traumatic Brain Injury - Pipeline by Cognosci Inc, 2022
Traumatic Brain Injury - Pipeline by Complement Pharma BV, 2022
Traumatic Brain Injury - Pipeline by Covis Pharmaceuticals Inc, 2022
Traumatic Brain Injury - Pipeline by Deha Pharmaceutical LLC, 2022
Traumatic Brain Injury - Pipeline by Eagle Pharmaceuticals Inc, 2022
Traumatic Brain Injury - Pipeline by Eisai Co Ltd, 2022
Traumatic Brain Injury - Pipeline by Emerald Organic Products Inc, 2022
Traumatic Brain Injury - Pipeline by Epigen Biosciences Inc, 2022
Traumatic Brain Injury - Pipeline by Expesicor Inc, 2022
Traumatic Brain Injury - Pipeline by Fortuna Fix Inc, 2022
Traumatic Brain Injury - Pipeline by GABA Therapeutics Inc, 2022
Traumatic Brain Injury - Pipeline by GNT Pharma Co Ltd, 2022
Traumatic Brain Injury - Pipeline by Gryphon Therapeutics Inc, 2022
Traumatic Brain Injury - Pipeline by Hemarina SA, 2022
Traumatic Brain Injury - Pipeline by Hibernaid Inc, 2022
Traumatic Brain Injury - Pipeline by Hillhurst Biopharmaceuticals Inc, 2022
Traumatic Brain Injury - Pipeline by Hope Biosciences LLC, 2022
Traumatic Brain Injury - Pipeline by Hopstem Biotechnology LLC, 2022
Traumatic Brain Injury - Pipeline by Hoverink Biotechnologies Inc, 2022
Traumatic Brain Injury - Pipeline by ImmunoChem Therapeutics LLC, 2022
Traumatic Brain Injury - Pipeline by Inflammatory Response Research Inc, 2022
Traumatic Brain Injury - Pipeline by International Stem Cell Corp, 2022
Traumatic Brain Injury - Pipeline by Ischemix Inc, 2022
Traumatic Brain Injury - Pipeline by JT Pharmaceuticals Inc, 2022
Traumatic Brain Injury - Pipeline by Jupiter Neurosciences Inc, 2022
Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals Inc, 2022
Traumatic Brain Injury - Pipeline by M et P Pharma AG, 2022
Traumatic Brain Injury - Pipeline by Mapreg SAS, 2022
Traumatic Brain Injury - Pipeline by Mercaptor Discoveries Inc, 2022
Traumatic Brain Injury - Pipeline by NervGen Pharma Corp, 2022
Traumatic Brain Injury - Pipeline by NeuExcell Therapeutics Inc, 2022
Traumatic Brain Injury - Pipeline by NeurAegis Inc, 2022
Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Ltd, 2022
Traumatic Brain Injury - Pipeline by NeurExo Sciences LLC, 2022
Traumatic Brain Injury - Pipeline by Neurodon LLC, 2022
Traumatic Brain Injury - Pipeline by Neuronasal LLC, 2022
Traumatic Brain Injury - Pipeline by NeuroNascent Inc, 2022
Traumatic Brain Injury - Pipeline by Neuropathix Inc, 2022
Traumatic Brain Injury - Pipeline by Neuroplast BV, 2022
Traumatic Brain Injury - Pipeline by NeuroTheranostics Inc, 2022
Traumatic Brain Injury - Pipeline by NeuroTrauma Sciences LLC, 2022
Traumatic Brain Injury - Pipeline by New World Laboratories Inc, 2022
Traumatic Brain Injury - Pipeline by NoNO Inc, 2022
Traumatic Brain Injury - Pipeline by Noveome Biotherapeutics Inc, 2022
Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, 2022
Traumatic Brain Injury - Pipeline by Nyrada Inc, 2022
Traumatic Brain Injury - Pipeline by Odyssey Health Inc, 2022
Traumatic Brain Injury - Pipeline by OncoSynergy Inc, 2022
Traumatic Brain Injury - Pipeline by Orpheris Inc, 2022
Traumatic Brain Injury - Pipeline by Oxeia Biopharmaceuticals Inc, 2022
Traumatic Brain Injury - Pipeline by Palisade Bio, Inc, 2022
Traumatic Brain Injury - Pipeline by Peptron Inc, 2022
Traumatic Brain Injury - Pipeline by Personalized Stem Cells Inc, 2022
Traumatic Brain Injury - Pipeline by PharmaTher Holdings Ltd, 2022
Traumatic Brain Injury - Pipeline by PharmatrophiX Inc, 2022
Traumatic Brain Injury - Pipeline by Pinteon Therapeutics Inc, 2022
Traumatic Brain Injury - Pipeline by Praetego Inc, 2022
Traumatic Brain Injury - Pipeline by ProNeurogen Inc, 2022
Traumatic Brain Injury - Pipeline by ProThera Biologics Inc, 2022
Traumatic Brain Injury - Pipeline by Protheragen Inc, 2022
Traumatic Brain Injury - Pipeline by PurMinds NeuroPharma Inc, 2022
Traumatic Brain Injury - Pipeline by Qrons Inc, 2022
Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals Inc, 2022
Traumatic Brain Injury - Pipeline by Resolys Bio Inc, 2022
Traumatic Brain Injury - Pipeline by Revalesio Corp, 2022
Traumatic Brain Injury - Pipeline by Revive Therapeutics Ltd, 2022
Traumatic Brain Injury - Pipeline by RHNanopharmacuticals LLC, 2022
Traumatic Brain Injury - Pipeline by Rubicon Biotechnology Inc, 2022
Traumatic Brain Injury - Pipeline by Samus Therapeutics Inc, 2022
Traumatic Brain Injury - Pipeline by SanBio Co Ltd, 2022
Traumatic Brain Injury - Pipeline by SciSparc Ltd, 2022
Traumatic Brain Injury - Pipeline by Shinkei Therapeutics LLC, 2022
Traumatic Brain Injury - Pipeline by Silver Creek Pharmaceuticals Inc, 2022
Traumatic Brain Injury - Pipeline by SL Bigen Co Ltd, 2022
Traumatic Brain Injury - Pipeline by Spinogenix Inc, 2022
Traumatic Brain Injury - Pipeline by STATegics Inc, 2022
Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies Inc, 2022
Traumatic Brain Injury - Pipeline by Swedish Orphan Biovitrum AB, 2022
Traumatic Brain Injury - Pipeline by Synaptogenix Inc, 2022
Traumatic Brain Injury - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Traumatic Brain Injury - Pipeline by Tetra Therapeutics, 2022
Traumatic Brain Injury - Pipeline by Thera Neuropharma Inc, 2022
Traumatic Brain Injury - Pipeline by Therapeutic Solutions International Inc, 2022
Traumatic Brain Injury - Pipeline by Theratome Bio Inc, 2022
Traumatic Brain Injury - Pipeline by TikoMed AB, 2022
Traumatic Brain Injury - Pipeline by Trigemina Inc, 2022
Traumatic Brain Injury - Pipeline by vasopharm GmbH, 2022
Traumatic Brain Injury - Pipeline by Ventus Therapeutics Inc, 2022
Traumatic Brain Injury - Pipeline by VG Life Sciences Inc, 2022
Traumatic Brain Injury - Pipeline by Virogenomics BioDevelopment Inc, 2022
Traumatic Brain Injury - Pipeline by Vitro Diagnostics Inc, 2022
Traumatic Brain Injury - Pipeline by Vivazome Therapeutics Pty Ltd, 2022
Traumatic Brain Injury - Pipeline by Wesana Health, 2022
Traumatic Brain Injury - Pipeline by Xonovo Inc, 2022
Traumatic Brain Injury - Pipeline by ZyVersa Therapeutics Inc, 2022
Traumatic Brain Injury - Dormant Projects, 2022
Traumatic Brain Injury - Dormant Projects, 2022 (Contd..1)
Traumatic Brain Injury - Dormant Projects, 2022 (Contd..2)
Traumatic Brain Injury - Dormant Projects, 2022 (Contd..3)
Traumatic Brain Injury - Dormant Projects, 2022 (Contd..4)
Traumatic Brain Injury - Dormant Projects, 2022 (Contd..5)
Traumatic Brain Injury - Discontinued Products, 2022

List of Figures
Number of Products under Development for Traumatic Brain Injury, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Dental Imaging Systems: Global Markets

Dental Imaging Systems: Global Markets

Telecom operators’ strategies in the health market

Telecom operators’ strategies in the health market

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline